-
Can We Prevent CAR T-Associated Neurotoxicity Without Compromising Efficacy?
At EBMT25, Dr. Janaki Manoja Vinnakota presented compelling data on the role of microglial TAK1 activation in the development of CAR T cell therapy-associated neurotoxicity (ICANS). In her presentation titled…
-
EAU 2025 | Dr. Ashwin Sachdeva: ADT Therapy for mHSPC Upgraded—Combination with Metformin Improves Survival in High-Volume Patients and Reduces Metabolic Syndrome Risk
Currently, ADT remains the cornerstone treatment regimen for mHSPC. However, long-term use of ADT may increase the risk of cardiovascular events. Recently, the data from the STAMPEDE study presented at the European Association of Urology (EAU) Congress showed that the combination of metformin and ADT can extend the overall survival of patients with high tumor…
-
EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment
Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive…
-
EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients
For patients with non-muscle-invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy, clinicians and researchers are actively exploring novel treatment strategies. Among these, oncolytic virus therapy has emerged as a promising approach. At the 40th Annual EAU Congress, Dr. Siamak Daneshmand from the University of Southern California (USC) presented two key…
-
EAU 2025 | Non-Invasive Evaluation of Tumor Heterogeneity in BCR: Professor Xuefeng Qiu Shares Advancements and Clinical Experience with PSMA-PET/CT at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University
In recent years, prostate-specific membrane antigen (PSMA) molecular imaging technology has demonstrated significant value in the diagnosis and treatment of prostate cancer. It has improved the accuracy of clinical staging, supported multimodal treatment decision-making, and facilitated the development of precision medicine through novel radioligand therapies. At the recent EAU Congress, UroStream invited Professor Xuefeng Qiu…
-
Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment
The St. Gallen International Breast Cancer Conference (SGBCC) is one of the most authoritative and influential global events in the field of breast cancer, dedicated to advancing standardized diagnosis and treatment for early-stage breast cancer. To integrate international frontier concepts with domestic clinical practice and align China’s breast cancer care with global standards—ultimately delivering superior…
-
Advancing Prostate Cancer Diagnosis: Professor Declan Murphy Presents Results from the TRANSLATE Trial Comparing TP vs TRUS Biopsy
At the highly anticipated Game Changer Session at EAU25, Professor Declan Murphy (Peter MacCallum Cancer Centre, Melbourne) delivered an impactful presentation on the results of the TRANSLATE trial, a multicentre,…
-
EBMT 2025 | Post-Transplant Outcomes in AML with Haploidentical Donors
At the 51st Annual Meeting of EBMT, Dr. Eduardo Rodríguez-Arbolí presented important long-term data from an ALWP-EBMT study focusing on patients with acute myeloid leukemia (AML) who underwent haploidentical HSCT…
Connecting Medical Expertise through Media